logo-loader
Pharmaxis Ltd

Result of AGM

/**/ link{ color: blue }visited{ color: #954F72 } .aq{size:595.3pt 841.9pt;margin:2.0cm 2.0cm 42.55pt 2.0cm;}div.aq{}p.ca{margin-right:0cm;margin-left:0cm;text-align:justify;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: left}span.cb{color: black; font-family: "Calibri","sans-serif"; font-weight: bold}p.cc{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:12.0pt;font-family:"Calibri","sans-serif";}span.bv{color:black}span.ai{}table.cd{width:487.2pt;margin-left:-10.8pt;border-collapse:collapse}tr.bk{height:30.8pt} td.bs{width:64.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:30.8pt}p.ce{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold}span.bu{font-size:10.0pt;color:black}td.bq{width:66.05pt;padding:0cm 5.4pt 0cm 5.4pt; height:30.8pt}p.cf{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: right}td.bp{width:44.7pt;padding:0cm 5.4pt 0cm 5.4pt; height:30.8pt}td.bo{width:65.75pt;padding:0cm 5.4pt 0cm 5.4pt; height:30.8pt}td.bn{width:27.4pt;padding:0cm 5.4pt 0cm 5.4pt; height:30.8pt}td.bm{width:69.3pt;padding:0cm 5.4pt 0cm 5.4pt; height:30.8pt}td.bl{width:74.1pt;padding:0cm 5.4pt 0cm 5.4pt; height:30.8pt} td.bj{width:64.3pt;padding:0cm 5.4pt 0cm 5.4pt}td.bg{width:66.05pt;padding:0cm 5.4pt 0cm 5.4pt}p.cg{margin:0cm;margin-bottom:.0001pt;text-align:justify;font-size:12.0pt;font-family:"Calibri","sans-serif";text-align: right}span.bi{font-size:10.0pt}td.bf{width:44.7pt;padding:0cm 5.4pt 0cm 5.4pt}td.be{width:65.75pt;padding:0cm 5.4pt 0cm 5.4pt}td.bd{width:27.4pt;padding:0cm 5.4pt 0cm 5.4pt}td.bc{width:69.3pt;padding:0cm 5.4pt 0cm 5.4pt}td.bb{width:74.1pt;padding:0cm 5.4pt 0cm 5.4pt}table.ch{margin-left:-12.75pt;border-collapse:collapse} td.az{width:67.45pt;padding:0cm 5.4pt 0cm 5.4pt}td.ay{width:399.7pt;padding:0cm 5.4pt 0cm 5.4pt}span.ci{color:black}p.cj{margin-right:0cm;margin-left:0cm;text-align:justify;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt}span.aw{font-family: "Calibri","sans-serif";color:black}table.ck{margin-left:-5.4pt;border-collapse:collapse}td.at{width:214.6pt;padding:0cm 5.4pt 0cm 5.4pt}span.au{font-size:11.0pt}p.cl{margin-right:0cm;margin-left:0cm;text-align:justify;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt}link,span.d{color:blue;text-decoration:underline;} /**/
RNS Number : 8597O
Provexis PLC
04 October 2019
 

4 October 2019

 

Provexis plc

 

("Provexis" or the "Company")

 

Result of AGM

 

Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces that at the Company's Annual General Meeting, held earlier today, all resolutions were passed on a show of hands. The proxy votes received from shareholders on each resolution are set out below.

 

Resolutions

Votes for

*

%

Votes against

 

%

Votes total

**

Votes withheld

***

Resolution 1

236,549,625

99.99

13,361

0.01

236,562,986

300,000

Resolution 2

236,275,612

100.00

1,240

0.00

236,276,852

586,134

Resolution 3

236,158,555

99.98

41,763

0.02

236,200,318

662,668

Resolution 4

236,275,612

100.00

1,240

0.00

236,276,852

586,134

Resolution 5

234,736,711

99.33

1,592,616

0.67

236,329,327

533,659

Resolution 6

231,213,811

97.85

5,088,982

2.15

236,302,793

560,193

Resolution 7

230,838,811

97.59

5,695,166

2.41

236,533,977

329,009

Resolution 8

235,036,711

99.45

1,292,616

0.55

236,329,327

533,659

 

*

Includes discretionary votes

**

Total votes cast do not include withheld votes

***

A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes 'For' or 'Against' any of the resolutions

 

For further information please contact:

 

Provexis plc

Dawson Buck, Chairman

Ian Ford, CEO & CFO

 

Tel:        07490 391888

                [email protected]

Allenby Capital Limited

Nick Naylor / Liz Kirchner

Tel:        020 3328 5656

 

 

 

Notes for editors

 

About Provexis plc

AIM-listed Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.

 

Provexis was founded in 1999 and is headquartered in Reading, Berkshire.

 

Provexis shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.

 

For further information, please visit www.provexis.com and www.fruitflowplus.com.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
RAGLZLFBKBFFFBD

Quick facts: Pharmaxis Ltd

Price: 0.225

Market: ASX
Market Cap: $88.8 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Pharmaxis hopeful of FDA approval for cystic fibrosis inhalation medicine...

Pharmaxis Ltd (ASX:PXS) chief executive officer Gary Phillips updates Proactive Investors on the FDA approval timeframe for the company’s Bronchitol inhalation medicine used to treat adult cystic fibrosis patients. The healthcare-focused company is confident it will meet information...

on 13/8/19